EUVIMEDEUVIMED entdecken
Crossref

Diagnosis and management of immune checkpoint inhibitor–associated nephrotoxicity: a position statement from the American Society of Onco-nephrology

Sandra M Herrmann, Ala Abudayyeh, Shruti Gupta, Prakash Gudsoorkar, Nattawat Klomjit, Shveta S Motwani, Sabine Karam, Verônica T Costa E Silva, Sheikh B Khalid, Shuchi Anand, Jaya Kala, David E Leaf und 4 weitere

Kidney International · 2025-01 · 107 (1) · 21-32

DOI: 10.1016/j.kint.2024.09.017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Kidney International, 2025-01. Verfasst von Sandra M Herrmann und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: herrmann.sandra@mayo.edu. Hauptthemen laut MEDLINE: Acute Kidney Injury, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 74-mal zitiert (Crossref) und nennt 86 Literaturangaben. Gefördert von: Janssen Canada, Amgen, Mayo Clinic.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer and are now the backbone of therapy for several malignancies. However, ICIs can cause a spectrum of kidney immune-related adverse events including acute kidney injury (AKI), most commonly manifesting as acute interstitial nephritis (AIN), although glomerular disease and electrolyte disturbances have also been reported. In this position statement by the American Society of Onco-nephrology (ASON), we summarize the incidence and risk factors for ICI-AKI, pathophysiological mechanisms, and clinicopathologic features of ICI-AKI. We also discuss novel diagnostic approaches and promising biomarkers for ICI-AKI. From expert panel consensus, we provide clinical practice points for the initial assessment and diagnosis of ICI-AKI, management and immunosuppressive therapy, and consideration for rechallenge with ICI following AKI episodes. In addition, we explore ICI use in special populations, such as kidney transplant recipients, and propose key areas of focus for future research and clinical investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Kidney InjuryImmune Checkpoint InhibitorsHumansBiomarkersImmunosuppressive AgentsIncidenceKidney TransplantationNeoplasmsNephritis, InterstitialNephrologyRisk FactorsSocieties, MedicalUnited States

Stichwörter der Autor:innen

acute interstitial nephritisacute kidney injuryimmune checkpoint inhibitorsimmune-related adverse event

Substanzen

BiomarkersImmune Checkpoint InhibitorsImmunosuppressive Agents

Autor:innen und Institutionen

  • Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: herrmann.sandra@mayo.edu.
  • Section of Nephrology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
  • Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA; Department of Medical Oncology, Dana-Farber Cancer Instit…
  • Division of Nephrology, University of Cincinnati, Cincinnati, Ohio, USA.
  • Department of Medicine, Division of Nephrology and Hypertension, University of Minnesota, Minneapolis, Minnesota, USA.
  • Department of Medical Oncology, Dana-Farber Cancer Institute. Harvard Medical School, Boston, Massachusetts, USA.

Förderung

  • Janssen Canada
  • Amgen
  • Mayo Clinic
  • National Institutes of Health

Zitieren

APA

Herrmann, S. M., Abudayyeh, A., Gupta, S., Gudsoorkar, P., Klomjit, N., Motwani, S. S., Karam, S., Costa E Silva, V. T., Khalid, S. B., Anand, S., Kala, J., Leaf, D. E., Murakami, N., Rashidi, A., Wanchoo, R., & Kitchlu, A. (2025). Diagnosis and management of immune checkpoint inhibitor–associated nephrotoxicity: a position statement from the American Society of Onco-nephrology. Kidney International, 107(1), 21-32. https://doi.org/10.1016/j.kint.2024.09.017

Vancouver

Herrmann SM, Abudayyeh A, Gupta S, Gudsoorkar P, Klomjit N, Motwani SS, et al. Diagnosis and management of immune checkpoint inhibitor–associated nephrotoxicity: a position statement from the American Society of Onco-nephrology. Kidney International. 2025;107(1):21-32. doi:10.1016/j.kint.2024.09.017

BibTeX
@article{Herrmann2025,
  author = {Herrmann, Sandra M and Abudayyeh, Ala and Gupta, Shruti and Gudsoorkar, Prakash and Klomjit, Nattawat and Motwani, Shveta S and Karam, Sabine and Costa E Silva, Verônica T and Khalid, Sheikh B and Anand, Shuchi and Kala, Jaya and Leaf, David E and Murakami, Naoka and Rashidi, Arash and Wanchoo, Rimda and Kitchlu, Abhijat},
  title = {Diagnosis and management of immune checkpoint inhibitor–associated nephrotoxicity: a position statement from the American Society of Onco-nephrology},
  journal = {Kidney International},
  year = {2025},
  volume = {107},
  number = {1},
  pages = {21--32},
  doi = {10.1016/j.kint.2024.09.017}
}
Kostenlos starten →